No Data
No Data
Earnings Preview: EYPT to Report Financial Results on March 05
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 30% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Express News | Traders Circulate Unconfirmed Report On Social Media That Eyepoint Pharmaceuticals Received National Medical Products Administration Approval Of Dexycu In China To Treat Post-Operative Inflammation Following Ocular Surgery
10 Health Care Stocks Whale Activity In Today's Session
$EYPT Stock Is up 10% Today. Here's What We See in Our Data.
Mizuho Securities Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating
Daight : easy way to confirm just check if the boss is has any connections to CCP or not.![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)